Jazz Pharmaceuticals plc

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-06 EDT			5-day change	1st Jan Change
106.3 ^USD	-0.24%		+0.82%	-13.56%

06-06	Transcript : Jazz Pharmaceuticals plc Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 02:00 PM
06-01	Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024	CI

Jazz Pharmaceuticals : Announces First Quarter 2024 Financial Results

May 02, 2024 at 09:57 am

This page provides announcements from The Bermuda Stock Exchange (BSX) and regulatory news filings by issuers listed on the BSX. Please note the BSX is not responsible for the content, accuracy or completeness of announcements filed by issuers and disclaims all liability for any loss arising from reliance on information contained within issuer announcements.

Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results 02 May 2024

Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results

Attachments

Original Link
Permalink

Disclaimer

Jazz Pharmaceuticals plc published this content on 02 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 May 2024 13:52:28 UTC.

Latest news about Jazz Pharmaceuticals plc

Transcript : Jazz Pharmaceuticals plc Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 02:00 PM	06-06
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024	06-01	CI
Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board	05-31	CI
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024	05-30	CI
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday	05-29	MT
Jazz Pharmaceuticals Says US FDA Grants Zanidatamab Priority Review to Treat HER2-Positive Metastatic Biliary Tract Cancer	05-29	MT
Jazz Pharmaceuticals plc Announces the U.S. Food and Drug Administration Accepted and Granted Priority Review of the Biologics License Application for Zanidatamab	05-29	CI
Transcript : Jazz Pharmaceuticals plc Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM	05-15
US reclassification could drive fresh research funding into pot sector	05-13	RE
Jazz Pharmaceuticals Insider Sold Shares Worth $548,250, According to a Recent SEC Filing	05-07	MT
UBS Adjusts Price Target on Jazz Pharmaceuticals to $117 From $121, Maintains Neutral Rating	05-03	MT
Jazz Pharmaceuticals Q1 Adjusted Earnings Decline, Revenue Rises; Reaffirms 2024 Outlook	05-02	MT
(JAZZ) JAZZ PHARMACEUTICALS Forecasts Fiscal Year 2024 EPS Range $18.15 - $19.35	05-01	MT
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Reports Q1 Revenue $902M, vs. Street Est of $954.3M	05-01	MT
Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS Posts Q1 EPS $2.68, vs. Street Est of $4.18	05-01	MT
Transcript : Jazz Pharmaceuticals plc, Q1 2024 Earnings Call, May 01, 2024	05-01
Jazz Pharmaceuticals plc Affirms Earnings Guidance for the Full Year 2024	05-01	CI
Jazz Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment	04-02	MT
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer	04-02	CI
JPMorgan Raises Jazz Pharmaceuticals' Price Target to $190 From $170, Maintains Overweight Rating	03-25	MT
Piper Sandler Adjusts Price Target on Jazz Pharmaceuticals to $188 From $171, Maintains Overweight Rating	03-20	MT
Transcript : Jazz Pharmaceuticals plc - Special Call	03-19
Stifel Raises Jazz Pharmaceuticals' Price Target to $230 From $225, Maintains Buy Rating	03-15	MT
H.C. Wainwright Cuts Price Target on Jazz Pharmaceuticals to $200 From $204, Maintains Buy Rating	03-14	MT

Chart Jazz Pharmaceuticals plc

Duration

Period

More charts

Company Profile

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Companyâs lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Sector

Pharmaceuticals

Calendar

2024-06-12 - Goldman Sachs Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Jazz Pharmaceuticals plc

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

106.3 USD

Average target price

180.3 USD

Spread / Average Target

+69.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JAZZ PHARMACEUTICALS PLC	-13.56%	6.7B
ELI LILLY AND COMPANY	+43.64%	754B
NOVO NORDISK A/S	+39.48%	630B
JOHNSON & JOHNSON	-6.58%	352B
MERCK & CO., INC.	+19.72%	331B
ABBVIE INC.	+8.78%	298B
NOVARTIS AG	+11.75%	217B
ROCHE HOLDING AG	-1.64%	216B
PFIZER, INC.	+0.03%	163B
AMGEN INC.	+6.13%	164B

Other Pharmaceuticals

Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Jazz Pharmaceuticals : Announces First Quarter 2024 Financial Results

EPS Revisions